Celgene Corporation (NASDAQ:CELG) today announced that results of a
study evaluating the combination of REVLIMID® (lenalidomide) with
rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine
sulfate and prednisone (R-CHOP) in untreated diffuse large b-cell
lymphoma (DLBCL) were published online ahead of print in the Journal
of Clinical Oncology .
for Clinical Study in the Journal of Clinical Oncology Reports Patients with Diffuse Large B-Cell Lymphoma Receiving Oral REVLIMID with Standard R-CHOP Achieved 98% Overall Response Rate and 80% Complete Response Rate investment picks